CXCL16 and acute lymphoblastic leukemia: Our findings revealed significant increases in the secretion of IL-5, CXCL5, CCL5, and CXCL16 in SupB15 cells following rhIL-17A treatment, and among these four cytokines, CXCL16 exhibited the most robust secretion from Ph+ B-ALL cells (Fig. 5d).